Field Medical Raises $35M to Push Forward VT Ablation Trial with Next-Gen PFA Tech

Field Medical has secured $35 million in Series B financing to accelerate development of its pulsed field ablation (PFA) platform and kickstart a pivotal clinical trial targeting ventricular tachycardia (VT), a difficult and under-addressed cardiac condition. The round was co-led by BioStar Capital and Cue Growth, with continued backing from existing strategic investors.

The funds will be used to initiate the VERITAS trial, advance product development of the FieldForce™ Ablation System, and support regulatory growth. That system is designed to deliver fast, transmural ablation in VT patients, offering a new toolset for electrophysiologists who’ve had limited options.

Momentum from Field Medical’s strong pilot data presented at the 2025 Heart Rhythm Society meeting helped drive investor confidence. That momentum now puts the company’s total funding at $75 million since its founding in 2022.

A new regulatory update from the FDA last month also gave a boost to companies in the Breakthrough Device Designation pipeline, with a new TAP Pilot Program milestone outlined for later this summer.

“Ventricular tachycardia is among the most underpenetrated segments in electrophysiology, yet physicians still lack the tools they need,” said Steven Mickelsen, MD, founder and CEO of Field Medical, highlighting the significance of the announcement.

Field’s board is also getting a refresh. Joining the leadership team are several industry veterans including Mark Wisniewski, CFO at Enterra Medical, who now chairs the Field board, and Marlou Janssen, former President of Biotronik U.S. Ben Cannon from Cue Growth also joins, bringing experience from scaling growth-stage health tech ventures.

The company’s FieldForce™ system, featuring its proprietary FieldBending™ energy delivery, has already been recognized by the FDA with Breakthrough status and is one of the few technologies accepted into the TAP Pilot Program for VT care.